Det danske vaccinationsprogram fortsætter uden J&J-vaccinen.

Går man op i det, så læs dette grundige og lettilgængelige notat fra @SSTSundhed som redegør for alle mellemregninger.

Hovedbudskaber opsummeret i tråd nedenfor 👇

sst.dk/da/Udgivelser/…
Inden jeg tager fat på notatet, så lad mig pege på en ekstremt hyppig misforståelse: X ugers forsinkelse (her 1-4 uger) er IKKE lig med en tilsvarende forsinkelse af genåbning. Genåbning afhænger af mange faktorer udover vacciner og langt de fleste går den rigtige vej for os 💪
Notatet redegør for risiko for VITT, dvs. de sjældne men meget alvorlige bivirkninger, ved J&J-vaccinen. Samlet antages risiko at være sammenlignelig mellem J&J og AstraZeneca-vaccinen. Yderst rimelig antagelse.
Den tabte beskyttelse ved ikke at vaccinere (med J&J) er i notatet beregnet ekstremt konservativt, dvs. ved en urealistisk antagelse om fortsat smittetryk et stykke over hvad der reelt kan forventes. Trods det er de beregnede konsekvenser ganske små.
Eksempel: Blandt kvinder 30-34 vil udskydelsen "koste" 250 smittede, heraf vil 8-9 blive indlagt, 0 på intensiv. Dette skal sammenlignes med 1-6 tilfælde af VITT i samme gruppe ved brug af J&J. (Og igen: Ved konservativ antagelse om fortsat stor smitte!)
Gruppe 1-8 er færdigvaccinerede og gruppe 9 er godt igang. Forsinkelsen rammer således alene 10a-d. Selv her er forsinkelsen ret begrænset: 1-2 uger for de fleste, op til 4 uger for de 30-39-årige.
Foruden VITT-risiko ser der ud til at AZ og J&J medfører en let øget risiko for øvrige "venøse tromboembolier" (blodpropper i venerne). Langt mindre alvorlige end VITT, men taler også imod disse vacciner til i øvrigt raske unge.
Der er intet der tyder på VITT som bivirkning ved mRNA-vaccinerne (Moderna og PfizerBioNTech). Desuden har mRNA-vaccinerne vist bedre beskyttelse mod covid-19 end AZ og J&J-vaccinen. Slutteligt giver mRNA-vaccinerne mindre akutte bivirkninger ifm vaccination.
Frustrationerne er helt forståelige. Men i kampens hede overvurderer mange de afledte effekter af at udelade J&J fra vaccinationsprogrammet.

Med de data vi har, og det er efterhånden en del, så er der i min vurdering ikke anden meningsfuld beslutning end den der er truffet.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Anton Pottegård

Anton Pottegård Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Pottegard

26 Jun 20
THREAD:
Are you a journalist writing about the newest study by Didier Raoult on #hydroxychloroquine in #COVID19?

Allow me to point to a few issues...

TL;DR: One of the worst studies I have ever read. It provides zero evidence of clinical relevance!

sciencedirect.com/science/articl…
There are MANY issues that would individually make this useless. Considering them all, the paper is borderline nonsensical. We’re talking very fundamental flaws. As pointed out by others, they violate core principles that we have previously outlined.

Note that this study is OBSERVATIONAL. There is no randomization of patients. Such studies can be useful if, and only if, the study question lends itself to an observational design and if the study is performed correctly. Neither of these two criteria are met in this case.
Read 11 tweets
26 May 20
1/n
LOOKING FOR REVIEWERS! 🤓

We have just submitted a detailed description of 9500 Danish #COVID19 patients using the nationwide Danish health registries.

We are looking for INPUT from #epitwitter and others.

Details in THREAD below.

medrxiv.org/content/10.110…
2/n
We would love to receive input to our work, allowing us to prepare the best paper possible. It is currently submitted for review, and any useful input will be implemented into the revised manuscript (once we, fingers crossed, get to that part…)
3/n
Comments / suggestions can be provided directly at @medrxivpreprint (using the link above) or via mail to corresponding author (see the .pdf-paper).

We obviously cannot guarantee that we'll implement every suggestion made, but we promise to carefully consider all input!
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!